Aldosterone synthase inhibitors - Pipeline Insight, 2024

This “Aldosterone synthase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Aldosterone synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aldosterone synthase inhibitors Understanding

Aldosterone synthase inhibitors: Overview

Aldosterone synthase (CYP11ß2) is the terminal enzyme in the aldosterone biosynthetic pathway and is required for aldosterone biosynthesis. Inactivating mutations in aldosterone synthase induce Na+ wasting, hypotension and hyperkalemia in a rare autosomal recessive syndrome in humans. Increased aldosterone production is the pathophysiologic mechanism of primary aldosteronism, a prominent cause of secondary hypertension, suppressed PRA and hypokalemic metabolic alkalosis. Because aldosterone synthase (AS) is a key enzyme involved in the final three rate-limiting steps of the biosynthesis pathway of aldosterone, therefore its inhibition has been considered as an effective strategy to treat hypertension, heart failure, and related cardio-metabolic diseases.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Aldosterone synthase inhibitors R&D. The therapies under development are focused on novel approaches for Aldosterone synthase inhibitors.

Aldosterone synthase inhibitors Emerging Drugs Chapters

This segment of the Aldosterone synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aldosterone synthase inhibitors Emerging Drugs

MLS 101: Mineralys Therapeutics MLS 101 is a highly selective and potent aldosterone synthase inhibitor, that is being investigated for the treatment of hypertension. It selectively inhibits CYP11B2 pathway responsible for the synthesis of aldosterone and has no untoward effect of blocking the mineralocorticoid receptors, thereby significantly reducing plasma aldosterone levels without affecting other hormones like cortisol. Currently, it is in Phase II stage of clinical trial evaluation to treat hypertension.

DP13: Damian Pharma An aldosterone synthase inhibitor, DP13 is a first-of-its-kind treatment for PA that medically targets the cause of the disease. DAMIAN successfully completed its Phase I Clinical Trial evaluating the pharmacological properties of DP13 in healthy volunteers. The safety and efficacy of DP13 is currently being investigated across Europe in patients with Primary Aldosteronism (PA) in a Phase II Trial.

Aldosterone synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Aldosterone synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aldosterone synthase inhibitors

There are approx. 4+ key companies which are developing the Aldosterone synthase inhibitors. The companies which have their Aldosterone synthase inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Mineralys Therapeutics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Aldosterone synthase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aldosterone synthase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aldosterone synthase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aldosterone synthase inhibitors drugs.

Aldosterone synthase inhibitors Report Insights

• Aldosterone synthase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aldosterone synthase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Aldosterone synthase inhibitors drugs?
• How many Aldosterone synthase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aldosterone synthase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aldosterone synthase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aldosterone synthase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mineralys Therapeutics
• DAMIAN PHARMA AG
• CinCor Pharma
• Laekna Therapeutics
• Angion Biomedica
• PhaseBio Pharmaceuticals

Key Products

• MLS 101
• DP13
• CIN 107
• LAE 001
• PB 6440

This product will be delivered within 1-3 business days.